P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

Tepotinib, a MET tyrosine kinase inhibitor, is approved for the treatment of advanced MET exon 14 (METex14) skipping NSCLC in several Asian countries. In the global VISION trial (Cohorts A+C; N=313), tepotinib demonstrated durable clinical activity with an objective response rate (ORR) of 51.4% and a median (m) duration of response (DOR) of 18.0 months in long-term follow-up (median 32.6 months; data cut-off: November 20, 2022). Here, we report outcomes in the subgroup of Asian patients.